Mostrar el registro sencillo

dc.contributor.authorPorebski, Bartlomiej
dc.contributor.authorChrist, Wanda
dc.contributor.authorCorman, Alba
dc.contributor.authorHaraldsson, Martin
dc.contributor.authorBarz, Myriam
dc.contributor.authorLidemalm, Louise
dc.contributor.authorHäggblad, Maria
dc.contributor.authorIlmain, Juliana
dc.contributor.authorWright, Shane C.
dc.contributor.authorMurga, Matilde
dc.contributor.authorSchlegel, Jan
dc.contributor.authorJarvius, Malin
dc.contributor.authorLapins, Maris
dc.contributor.authorSezgin, Erdinc
dc.contributor.authorBhabha, Gira
dc.contributor.authorLauschke, Volker M.
dc.contributor.authorCarreras-Puigvert, Jordi
dc.contributor.authorLafarga Coscojuela, Miguel Ángel 
dc.contributor.authorKlingström, Jonas
dc.contributor.authorHühn, Daniela
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-10-07T14:40:47Z
dc.date.available2024-10-07T14:40:47Z
dc.date.issued2024
dc.identifier.issn1525-0016
dc.identifier.issn1525-0024
dc.identifier.urihttps://hdl.handle.net/10902/34119
dc.description.abstractSeveral viruses hijack various forms of endocytosis in order to infect host cells. Here, we report the discovery of a molecule with antiviral properties that we named virapinib, which limits viral entry by macropinocytosis. The identification of virapinib derives from a chemical screen using high-throughput microscopy, where we identified chemical entities capable of preventing infection with a pseudotype virus expressing the spike (S) protein from SARS-CoV-2. Subsequent experiments confirmed the capacity of virapinib to inhibit infection by SARS-CoV-2, as well as by additional viruses, such as mpox virus and TBEV. Mechanistic analyses revealed that the compound inhibited macropinocytosis, limiting this entry route for the viruses. Importantly, virapinib has no significant toxicity to host cells. In summary, we present the discovery of a molecule that inhibits macropinocytosis, thereby limiting the infectivity of viruses that use this entry route such as SARS-CoV2.es_ES
dc.description.sponsorshipACKNOWLEDGMENTS: The authors acknowledge the support from the Chemical Biology Consortium Sweden (CBCS), node Uppsala university, a national research infrastructure funded by the Swedish Research Council (dr.nr.2021-00179) and SciLifeLab; Dr Lars Haag at the Electron Microscopy Unit, Karolinska Institutet for support with TEM experiments and the Bioinformatics and Expression Analysis facility, Karolinska Institutet, for help with RNA-seq. Research was funded by grants from the Cancerfonden foundation (CAN 21/1529) and the Swedish Research Council (538-2014-31) to O.F.-C.; the Swedish Society for Medical Research (P18-0098; PD20-0153) to S.C.W.; the Swedish Research Council (grant agreement nos. 2019-01837 and 2021-02801) and the EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant no. 875510) to V.M.L.; the Swedish Research Council Starting Grant (2020-02682) and Human Frontier Science Program (RGP0025/ 2022) to E.S.; and a Marie Skłodowska-Curie Actions Postdoctoral Fellowship (101059180) and a KI Virus Research Grant to J.S.es_ES
dc.format.extent13 p.es_ES
dc.language.isoenges_ES
dc.publisherAcademic Press/Cell Presses_ES
dc.rights© 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy. This is an open access article under the CC BY-NC-ND license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceMolecular Therapy, 2024, 39(9), 3012-3024es_ES
dc.subject.otherAntiviralses_ES
dc.subject.otherDrug developmentes_ES
dc.subject.otherChemical screenes_ES
dc.subject.otherSARS-CoV-2es_ES
dc.subject.otherMpox viruses_ES
dc.subject.otherTick-borne encephalitis viruses_ES
dc.subject.otherPseudotype viruses_ES
dc.subject.otherMacropinocytosises_ES
dc.titleDiscovery of a novel inhibitor of macropinocytosis with antiviral activityes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.ymthe.2024.06.038es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1016/j.ymthe.2024.06.038
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy. This is an open access article under the CC BY-NC-ND license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy. This is an open access article under the CC BY-NC-ND license.